FAPI PET/CT improves staging of newly diagnosed breast cancer

Toronto, Ontario—A comparative analysis between FAPI and ¹⁸F-FDG PET/CT for the systemic staging of newly diagnosed breast cancer shows that FAPI PET/CT is more accurate in staging patients. Nearly 20 percent of patients were restaged by FAPI PET/CT, indicating the radiotracer’s efficacies and benefits for clinical practice. This research was presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

¹⁸F-FDG PET/CT, while commonly used in breast cancer staging, has limitations, such as false positives in inflammatory breast lesions and reduced sensitivity in specific breast cancer subtypes. Previous small-sample retrospective studies suggest that ⁶⁸Ga-FAPI might outperform ¹⁸F-FDG PET/CT with its high sensitivity in the detection of primary tumors and metastases among breast cancer patients.

“There is currently a lack of evidence on the efficacy of FAPI PET/CT, especially in large sample cohorts,” said Zhixin Hao, MD, a nuclear medicine physician at Peking Union Medical College Hospital in Beijing, China. “Our study sought to add to the literature by assessing FAPI PET/CT for the systemic staging of newly diagnosed breast cancer compared with ¹⁸F-FDG PET/CT.”

A total of 121 patients newly diagnosed with breast cancer were included in the study. All patients underwent ¹⁸F-FDG imaging. In addition, 53 patients were imaged with ⁶⁸Ga-FAPI-04 PET/CT and 68 patients were imaged with A1¹⁸F-FAPI-04 PET/CT. Data was analyzed and lesions were recorded as positive if their uptake exceeded that of the adjacent background tissue. The TNM clinical stage was determined from ¹⁸F-FDG and FAPI PET/CT, according to the American Joint Committee on Cancer Staging Manual.

Compared to the clinical TNM stage determined by ¹⁸F-FDG PET/CT, FAPI re-staged 19.8 percent of patients. Management plans were optimized in six patients due to the additional detection of bone lesions and internal mammary lymph nodes.

Of note, FAPI PET/CT upstaged 21.7 percent of stage IIA patients by ¹⁸F-FDG PET/CT. According to Hao, patients with stage IIA BC should be considered for systemic staging with FAPI PET/CT at the time of initial diagnosis.

“This study is significant as it has the potential to advance personalized treatment strategies for breast cancer patients,” noted Hao. “FAPI PET/CT for the initial staging of breast cancer has the potential to reduce unnecessary treatments and improve patient outcomes.”

Abstract 242411. “FAPI Versus ¹⁸F-FDG PET/CT for Systemic Staging of Newly Diagnosed Breast Cancer,” Zhixin Hao, Bo Pan, Ru Yao, Yidong Zhou, Qiang Sun, Li Huo, Peking Union Medical College Hospital, Beijing, China.

Link to Session

###

All 2024 SNMMI Annual Meeting abstracts can be found online.

About the Society of Nuclear Medicine and Molecular Imaging

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

SNMMI’s members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit www.snmmi.org.

---

---